If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
148
results.
Updated on
15/07/2026 [07:22:00]
Results 25 to 50 of 148
Absstract of: WO2026141270A1
Provided is an information processing system that provides users more useful information for improving blood sugar levels. The information processing system acquires meal information about meals consumed by a user, and outputs recommendation information on the basis of the meal information, user information, blood glucose level information, and behavioral information. Additionally, the information processing system outputs predicted blood glucose levels on the basis of meal information, user information, blood glucose level information, and behavioral information, the predicted blood glucose levels being for the case in which the user consumes a meal corresponding to the meal information. The information processing system also outputs blood glucose level prediction information on the basis of the recommended information. Moreover, the information processing system provides the user with blood glucose level prediction information based on meal information, recommendation information, and blood glucose level prediction information based on the recommendation information.
Absstract of: WO2026143067A1
The present disclosure provides compositions of stem cell-derived pancreatic islet cells engineered for improved engraftment and methods of use thereof for treating a subject having an insulin deficiency.
Absstract of: US20260182845A1
0000 A wearable device for measuring blood glucose and blood pressure for a user includes a main body including a first side and a second side formed on the opposite side of the first side; a first supporting frame protruding from the first side and a second supporting frame protruding from the second side; a belt portion having a first belt end detachably coupled to the first supporting frame, a second belt end detachably coupled to the second supporting frame, and at least one aligning mark, wherein the belt portion is positioned around a wrist of the user; wherein the main body includes at least one pressure sensor array assembly overlaid on a radial artery of the user; wherein the pressure sensor array assembly includes a plurality of apertures arranged one after another to form a cross-shaped pattern and at least four sensor elements arranged in a symmetrical configuration.
Absstract of: US20260183397A1
0000 The present invention relates to a method for expansion of a population of lymphocytes in a controlled single culture vessel, the method comprising a step of (a) culturing a tissue or blood sample from a subject, which sample is known or suspected to contain lymphocytes; or (b) culturing lymphocytes, which lymphocytes are isolated from a tissue or blood sample from a subject; wherein the lymphocytes are expanded in a culture medium in which at least one of the following parameters is monitored and adjusted to a predefined value or range: pH, dissolved oxygen (DO) concentration, glucose concentration, lactate concentration and/or temperature; and wherein the method comprises a step of adjusting the culture volume to the expansion rate of the lymphocytes. Furthermore, the invention relates to a population of lymphocytes comprising at least 90% CD3+ T cells and less than 5% B cells, wherein at least 70% of said T cell portion are viable, optionally, and less than 10% are triple positive for CD45RA, CD57 and KLRG1.
Absstract of: WO2026142762A1
In an embodiment, a system for mitigating diabetic ketoacidosis (DKA) risk for a patient in real-time includes a continuous glucose monitoring (CGM) system configured to generate one or more glucose measurements associated with a cunent glucose level of a patient over a period, one or more memories including executable instructions, and one or more processors in data communication with the one or more memories. The one or more processors are configured to execute the executable instructions to receive glucose measurements for the patient from the CGM system, receive insulin data for the patient, evaluate criteria associated with DKA using first information related to the glucose measurements and second information related to the insulin data, detect a risk of DKA for the patient responsive to a combination of the first information and the second information satisfying the criteria associated with DKA, and alert the patient based on the detected risk.
Absstract of: WO2026142802A1
Certain aspects of the present disclosure provide a therapy management system configured to monitor at least glucose concentration levels of a patient during a first time period using one or more glucose sensors to obtain glucose data, and determine a diabetic state classification of the patient based on the glucose data. The diabetic state classification indicates a diabetic state of the patient and comprises one of: a healthy classification, a pre-diabetic classification, a mild type 2 diabetes (T2D) classification, a severe T2D classification, or a gestational diabetes classification. The therapy management system is further configured to provide personalized feedback to the patient based on the determined diabetic state classification, wherein the personalized feedback comprises a recommendation for at least one of an exercise session, a dietary change, a lifestyle modification, a medication adjustment, or a continuous glucose monitoring wear schedule.
Absstract of: WO2026142937A1
In some embodiments, a method of automatically adjusting insulin therapy for a patient includes receiving, at a device associated with the patient, one or more glucose measurements generated by a continuous glucose monitoring (CGM) system of the patient for a period. The method also includes determining, at the device, basal insulin data and bolus insulin data of the patient for the period. The method also includes determining, at the device, a relationship between the basal insulin data and the bolus insulin data. The method also includes generating, at the device, an insulin therapy instruction for the patient based on the one or more glucose measurements and the determined relationship between the basal insulin data and the bolus insulin data, where the insulin therapy instruction includes a total bolus amount.
Absstract of: WO2026142537A1
Present invention relates to a needle-free glucose measurement system which enable measurement of blood glucose level using concentration value of N2O molecule available in breath air, which comprises an electronic assembly (1.1) which stabilizes the temperature and flow of wavelength-adjustable laser light source (1.2) and controls wavelength, a laser-based sensor (1) which determines concentration values of N2O molecule by measuring the adsorption amount of detector (1.5) wherein beams coming from laser light source (1.2) are adsorbed by N2O molecules in the breath air in the adsorption cell (1.4), and a processor (2) which determine glucose values in the blood using the concentration data coming from laser-based sensor (1).
Absstract of: US20260182933A1
In accordance with some implementations, a method includes obtaining blood glucose (BG) data indicative of BG levels of an individual. The method includes obtaining a first sleepiness score associated with the individual. The method includes determining, based at least in part on the BG data, that a low blood sugar alert condition is satisfied. The method includes, in response to determining that the low blood sugar alert condition is satisfied, directing an alert subsystem to generate a first alert output based on the first sleepiness score.
Absstract of: EP4769427A1
This application discloses a method and device for detecting an anomaly of a signal from a physiological parameter detection apparatus, particularly a continuous glucose monitor, CGM, comprising: acquiring a working parameter of the physiological parameter detection apparatus, wherein the working parameter comprises a working current; determining whether the signal from the physiological parameter detection apparatus is abnormal based on the working parameter: and outputting a detection result. Through the foregoing solution, an anomaly of a signal from the physiological parameter detection apparatus can be effectively detected, thereby ensuring signal accuracy.
Absstract of: EP4767938A2
0001 The present disclosure relates to a continuous blood glucose measurement device and an applicator, wherein the continuous blood glucose measurement device is produced in a state in which a body attachment unit has been assembled inside an applicator, so as to minimize a user's additional work of attaching the body attachment unit to the body, thereby enabling the body attachment unit to be attached to the body only by simply activating the applicator. Particularly, the present invention provides a continuous blood glucose measurement device and an applicator, wherein the applicator comprises a plunger body disposed at a first locating in an inner space of a main case and configured to downwardly move to a second location according to a manipulation of a pressure button. The pressure button is configured to be mode-changeable from a first mode, in which pressurizing movement by pressurizing manipulation is prevented, to a second mode, in which the pressurizing movement by the pressurizing manipulation is allowed.
Absstract of: EP4769422A1
An insulin pump control method and apparatus, an artificial pancreatic closed-loop system, and a storage medium are provided. The method includes: acquiring first monitoring data of a target object, obtaining an injection dosage of a first injection according to a target model and the first monitoring data, and injecting the target object based on the injection dosage of the first injection. The target model is adjusted based on total dosages corresponding to historical prediction failures.
Absstract of: EP4767931A1
The present application provides an analyte sensor based on blood glucose monitoring. The analyte sensor comprises a substrate, a working electrode, a reference electrode, a counter electrode, and a sensing layer; the sensing layer is provided on the working electrode; the working electrode, reference electrode, and counter electrode are provided at surfaces of the substrate, and the two electrodes from the working electrode; the working electrode, reference electrode, and counter electrode located at the same surface of the substrate are spatially separated by a channel. The analyte sensor can be implanted into a human body for monitoring, and has the characteristics of good flexibility, small size, low manufacturing cost, simple process flow, and long-term monitoring.
Absstract of: EP4769421A1
0001 The invention discloses a closed-loop artificial pancreas system for safe infusion, during a long period of real-time blood glucose value loss, the closed-loop artificial pancreas system can enter a learning mode or a safe mode. Based on historical blood glucose values and finger blood glucose values, it continues to calculate the required insulin infusion amount for the patient and infuses an appropriate amount of insulin to the patient. It will not infuse an inappropriate amount of insulin or even interrupt insulin infusion due to the lack of real-time blood glucose value, avoiding life-threatening situations for the patient and benefiting the patient's treatment.
Absstract of: EP4767933A1
0001 A method for controlling glucose in a flexibly structured dual-hormone artificial pancreas that manages optional meal and/or exercise notifications using coordinated control actions, which comprises: measuring a plasma glucose signal; calculating an incremental plasma glucose measurement (y); defining a model for incremental plasma glucose; defining a carbohydrate intake as dependent on a carbohydrate content estimated by the patient; defining an expected postprandial incremental plasma glucose y*(s) depending on the insulin bolus administered; defining a corrected incremental plasma glucose y(s), a corrected insulin infusion u(s), and a corrected carbohydrate d(s) intake; defining a virtual control action µ(s), divided into regulatory actions µr and counter-regulatory actions µcr and calculating control actions using a 2-DOF feedback controller with a nominal value pre-filter Fr(s).
Absstract of: US20260174959A1
0000 A glucose data analysis system includes an on-body unit and a processor. The on-body unit is configured to measure glucose levels of a user. The processor is configured to receive therapy data of the user including glucose data monitored by the on-body unit, analyze daily glucose profiles of the glucose data over an analysis period by a machine learning model, group the daily glucose profiles into two or more patterns based on the analysis performed by the machine learning model, and output a report including identification of the two or more patterns associated with each daily glucose profile. Advantageously the system may identify and visualize patterns of glucose data, identify recurring patterns, identify correlations between patterns and external events (e.g., medication, meals, exercise, sleep, stress, etc.), reduce glycemic variability, streamline analysis with unsupervised machine learning (e.g., no training), and provide recommendations for user intervention or actions based on identified patterns.
Absstract of: US20260174953A1
Embodiments disclosed herein are directed to an applicator for inserting a cannula into a body of the user for delivering medication from a medication infusion device to the user. According to one aspect, an applicator device includes a cannula and an insertion needle configured to insert the cannula into a body of a user. The applicator can include features that control the geometry of the skin during insertion of the cannula to provide a more reliable depth and insertion angle for the cannula.
Absstract of: WO2026131972A1
The invention relates to a device for distributing and receiving a population of pancreatic islets heterogeneous in size, the device comprising a matrix having a first face opposite a second face, characterized in that the matrix comprises concentric channels centered on a center O, the channels have an opening for receiving the pancreatic cells, the opening leading out onto the first face, the opening extending over the entire length (L) of the channel, the opening having a width (I) taken along the section Si, the device being configured such that the widths of the opening of two adjacent channels have an equal or increasing value moving away from the center O and such that the widths of the opening of a channel closest to the center O and of a channel furthest from the center O have an increasing value moving away from the center O. The invention relates to the field of implantable devices, in particular artificial pancreas devices.
Absstract of: US20260174975A1
0000 This invention discloses a protective mechanism for insulin needles and an insulin injection device. Through the cooperation of a U-shaped reciprocating slot and a flexible wall, it is possible to automatically retract the needle tip after injection, and prevent it from being pushed out again, thus achieving the purpose of needle tip protection and avoiding reuse.
Absstract of: AU2024391032A1
Methods are disclosed for making a stem cell-derived islet-like cell (SC-IC) population, where such methods include culturing precursor cells such as pancreatic progenitor cells, pancreatic endocrine precursor cells or immature SC-ICs one or more differentiation mediums that promote the differentiation of the precursor cells to more differentiated cells to obtain an SC-IC population that includes mature pancreatic-beta-like cells. Also disclosed are cell-differentiating compositions useful in performing the methods and SC-IC populations obtained by performing the methods. Also disclosed are compositions and implantable devices comprising the SC-IC populations, which are useful thereof for treatment of metabolic disorders such as diabetes mellitus (diabetes).
Absstract of: US20260174960A1
Disclosed herein are systems and methods for the delivery of insulin and pramlintide using an automated insulin delivery system. In a first embodiment, a drug delivery system is configured to deliver independent doses of insulin and pramlintide. The system monitors the user's blood glucose level and determines when a meal is been ingested and, in response, delivers the dose of pramlintide which, in turn alters the required delivery of insulin. In the second embodiment, the drug delivery system is configured to deliver a co-formulation of insulin and pramlintide as basal doses. The total amount of pramlintide delivered in a most recent pre-determine period of time, for example, 24 hours, is used to alter the aggressiveness of the algorithm which determines the basal doses of the co-formulation.
Absstract of: WO2026130307A1
Provided are small-fragment RNA derived from a circular RNA and the use thereof in the treatment of diabetic vascular diseases. The nucleotide sequence of the small-fragment RNA is CUAGCCGAAUGUUAAAAAAU. The provided small-fragment RNA has the effects of well protecting and maintaining the biological functions of vascular endothelial cells, has good structural stability, has a long half-life in vivo, and has the advantages of low effective concentration, high biological safety, etc. The provided small-fragment RNA has good application potentials in the field of clinical nucleic acid drug development, and provides a new idea for the treatment of chronic progressive vascular lesions caused by diabetes.
Absstract of: US20260174969A1
0000 Diabetes management systems may include a glucose monitoring device adapted to transmit glucose data and at least one accessory in communication with the glucose monitoring device and adapted to provide at least one alarm or alert based on the glucose data.
Absstract of: AU2024395220A1
The present invention provides culture-derived berry cells compositions which have a high phenolic acid and low anthocyanins in their polyphenolic fraction, and are high in protein, low in sugar, and have a high antioxidation potential.
Nº publicación: US20260174399A1 25/06/2026
Applicant:
DEXCOM INC [US]
DexCom, Inc.
Absstract of: US20260174399A1
Data describing glucose measurements is received from a continuous glucose monitoring (CGM) system worn by a user and predicted glucose values during a future time period are generated for the user based on the data. A determination is made that at least one of the predicted glucose values satisfies a threshold value for an alert, which is associated with a prediction horizon that defines an amount of time prior to satisfaction of the threshold value for communicating the alert to the user. Output of the alert is caused responsive to determining that the at least one predicted glucose value satisfies the threshold value for the alert within the prediction horizon, relative to a current time. The prediction horizon is modified based on a user response to the alert. Output of a subsequent instance of the alert is caused based on the modified prediction horizon.
BOPI
Electronic site
